Alpha-methylhydrocinnamic acid is a synthetic organic compound that is a precursor to the production of the pharmaceutical drug, ibuprofen. It is an important intermediate in the synthesis of various pharmaceuticals, including NSAIDs. The compound is often studied for its potential in the development of new drugs with anti-inflammatory, analgesic, and antipyretic properties.'
| ID Source | ID |
|---|---|
| PubMed CID | 99862 |
| CHEMBL ID | 1741113 |
| SCHEMBL ID | 65930 |
| MeSH ID | M0445044 |
| Synonym |
|---|
| 1009-67-2 |
| nsc-243716 |
| nsc243716 |
| alpha-methylhydrocinnamic acid, 98% |
| alpha-methylhydrocinnamic acid |
| AKOS000345344 |
| 2-methyl-3-phenylpropanoic acid |
| 2-methyl-3-phenyl-propionic acid |
| 2-benzylpropionic acid |
| EN300-75110 |
| MLS-0466784.0001 |
| unii-hf5q3w2pvc |
| nsc 243716 |
| 2-methyl-3-phenylpropionic acid |
| benzenepropanoic acid, alpha-methyl- |
| hf5q3w2pvc , |
| SCHEMBL65930 |
| alpha-methyl-hydrocinnamic acid |
| 2-benzylpropanoic acid |
| AKOS016038108 |
| mfcd00192301 |
| CHEMBL1741113 |
| benzenepropanoic acid, .alpha.-methyl- |
| 2-methyl-3-phenylpropanoic acid # |
| J-000291 |
| CS-0106156 |
| AS-44276 |
| AMY25510 |
| A897280 |
| alpha -methylhydrocinnamic acid |
| SY185587 |
| Z513624710 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic studies demonstrated 90% oral bioavailability of 2 SCFADs, and targeted plasma levels were maintained for several hours after single oral doses equivalent to 10% to 20% of doses required for butyrate." | ( Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Boosalis, MS; Dover, GJ; Faller, DV; Pace, BS; Perrine, SP; White, GL, 2002) | 0.31 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Apoptotic peptidase activating factor 1 | Homo sapiens (human) | EC50 (µMol) | 100.0000 | 9.0800 | 30.2933 | 59.0000 | AID588572 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||